ArticleScientific reports2016
Genetically manipulated phages with improved pH resistance for oral administration in veterinary medicine.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 111 citations in OpenAlex.
- Isolation and characterization of bacteriophages with lytic activity against multidrug-resistant non-typhoidal Salmonella from Nairobi City county, Kenya.BMC infectious diseases · 2025Article
- Anti-urease therapy: a targeted approach to mitigating antibiotic resistance in Helicobacter pylori while preserving the gut microflora.Gut pathogens · 2025Review
- The change of long tail fibers expanded the host range of a T5-like Salmonella phage and its application in milk.BMC microbiology · 2025Article
- The role of gut microbiota in diarrhea and its alleviation through microbiota-targeted interventions.Frontiers in microbiology · 2025Review
- A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.Antibiotics (Basel, Switzerland) · 2024Review
- Benefits and Challenges of Applying Bacteriophage Biocontrol in the Consumer Water Cycle.Microorganisms · 2024Review
- Therapeutics and prophylactic efficacy of novel lytic Escherichia phage vB_EcoS_PJ16 against multidrug-resistant avian pathogenic E. coli using in vivo study.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- An Overview of Diverse Strategies To InactivateEcoSal Plus · 2023Review
- Genetic Engineering and Biosynthesis Technology: Keys to Unlocking the Chains of Phage Therapy.Viruses · 2023Review
- Characterization and Comparative Genomic Analysis of Three VirulentInternational journal of molecular sciences · 2023Article
- Advancements in bacteriophage therapies and delivery for bacterial infection.Materials advances · 2023Review
- A review on the research progress on non-pharmacological therapy ofFrontiers in microbiology · 2023Review
- Selection and characterization of bacteriophages specific toVeterinary world · 2022Article
- An in vitro fermentation model to study the impact of bacteriophages targeting Shiga toxin-encoding Escherichia coli on the colonic microbiota.NPJ biofilms and microbiomes · 2022Article
- Enhancing the Stability of Bacteriophages Using Physical, Chemical, and Nano-Based Approaches: A Review.Pharmaceutics · 2022Review
- Article
- A novel lytic phage potentially effective for phage therapy against Burkholderia pseudomallei in the tropics.Infectious diseases of poverty · 2022Article
- Characterization and Genomic Analysis of a New Phage InfectingInternational journal of molecular sciences · 2022Article
- Article
- A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens.iScience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orally administered phages to control zoonotic pathogens face important challenges, mainly related to the hostile conditions found in the gastrointestinal tract (GIT). These include temperature, salinity and primarily pH, which is exceptionally low in certain compartments. Phage survival under these conditions can be jeopardized and undermine treatment. Strategies like encapsulation have been attempted with relative success, but are typically complex and require several optimization steps. Here we report a simple and efficient alternative, consisting in the genetic engineering of phages to display lipids on their surfaces. Escherichia coli phage T7 was used as a model and the E. coli PhoE signal peptide was genetically fused to its major capsid protein (10 A), enabling phospholipid attachment to the phage capsid. The presence of phospholipids on the mutant phages was confirmed by High Performance Thin Layer Chromatography, Dynamic Light Scattering and phospholipase assays. The stability of phages was analysed in simulated GIT conditions, demonstrating improved stability of the mutant phages with survival rates 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.